|
TRIP11 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.30489996164852E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.51539999998707E-07 |
| Normal-vs-Stage2 |
3.281100E-03 |
| Normal-vs-Stage3 |
1.81739999716157E-08 |
| Normal-vs-Stage4 |
1.28110000385817E-08 |
| Stage1-vs-Stage2 |
3.349200E-01 |
| Stage1-vs-Stage3 |
1.622450E-01 |
| Stage1-vs-Stage4 |
3.744200E-02 |
| Stage2-vs-Stage3 |
6.551900E-02 |
| Stage2-vs-Stage4 |
2.940300E-02 |
| Stage3-vs-Stage4 |
5.117600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.35389999714286E-08 |
| Normal-vs-AfricanAmerican |
1.192070E-02 |
| Normal-vs-Asian |
1.06560000001643E-06 |
| Caucasian-vs-AfricanAmerican |
3.106000E-01 |
| Caucasian-vs-Asian |
3.874400E-01 |
| AfricanAmerican-vs-Asian |
1.317810E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.69860039764569E-10 |
| Normal-vs-Female |
2.86829999973648E-07 |
| Male-vs-Female |
4.429900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.60289999998164E-06 |
| Normal-vs-Age(41-60Yrs) |
4.49489999665431E-08 |
| Normal-vs-Age(61-80Yrs) |
3.26839999953421E-07 |
| Normal-vs-Age(81-100Yrs) |
1.758170E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.515800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.971800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.500600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.476600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.789000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.982400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.041990E-02 |
| Classical-VS-Follicular |
2.017800E-01 |
| Classical-VS-Other |
1.165790E-01 |
| Classical-VS-Normal |
7.3275000000983E-07 |
| Tall-VS-Follicular |
2.203600E-01 |
| Tall-VS-Other |
4.977200E-01 |
| Tall-VS-Normal |
6.15480000298874E-08 |
| Follicular-VS-Other |
3.097400E-01 |
| Follicular-VS-Normal |
2.27529999996534E-06 |
| Other-VS-Normal |
1.344790E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.08839999527433E-08 |
| Normal-vs-N1 |
8.37450000457096E-08 |
| N0-vs-N1 |
1.785190E-01 |
|
|
